Today, we announced that we will be hosting a webcast to discuss new interim functional data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202, our next-generation investigational gene therapy for the treatment of Duchenne. Learn more: ir.regenxbio.com/news-releases/…

Welcome, REGENXBIO Summer Intern Class of 2025! We're thrilled to have this talented group join us and bring fresh perspectives, curiosity and energy. This summer, they'll be learning from our team of experts who are on a mission to improve lives through gene therapy.

Today we announced new positive interim functional data from our Phase I/II AFFINITY DUCHENNE trial of RGX-202. Learn more: ir.regenxbio.com/news-releases/… $RGNX

Last week, we hosted our 4th annual Science Showcase—featuring a symposium and poster session highlighting the innovation and collaboration driving our AAV Therapeutics. Thanks to our teams for your passion and impact. What we do truly matters.

This past weekend, a group of fearless REGENXBIO team members took on the Great Chesapeake Bay Swim in support of the Jett Foundation! We're proud to support families impacted by Duchenne—thank you, Jett Foundation, for all you do!

This #FathersDay, we honor the dads who are not only caregivers—but powerful advocates. Whether navigating a diagnosis, pushing for progress, or standing up for their children and loved ones, your strength and determination help drive change. Happy Father’s Day!

Our team hit the streets of Philadelphia for the 12th Annual Million Dollar Bike Ride! The Orphan Disease Center @ UPenn hosts this great event every year and has raised over $22 million. Our REGENXBIO riders always look forward to this opportunity to show our support for the rare disease community.

Our team enjoyed attending the 2025 Biotechnology Innovation Organization Innovation Organization International Convention this week in Boston! Our VP of Regulatory and Corporate Strategy, Nina Hunter, joined a panel of industry experts to discuss the future of early drug development.

We’re excited to share that REGENXBIO has been recognized as a 2025 Washington Post Top Workplaces winner — our fourth time participating in the survey and our fourth win! Thank you to our entire team for making REGENXBIO such a special place to work!

At our recent all-company meeting, we announced our CEO Award winner, Leiby Soto! Leiby is a true connector—someone who brings people together and helps create a culture where everyone feels like they belong. Join us in celebrating Leiby for this well-deserved recognition!

Happy Independence Day! Wishing you a safe and celebratory holiday.

Today, preclinical results supporting our investigational gene therapy program for Duchenne were published in the American Society of Gene and Cell Therapy's peer-reviewed journal, Molecular Therapy – Methods & Clinical Development. Learn more: lnkd.in/dt65gSjR

Meet Darrian, one of our interns! This summer, she has been making an impact on the Manufacturing Learning & Operational Excellence team by trying new tools and contributing to key projects. In her free time, she enjoys movies and dancing - a fun way to stay active and creative!

This month, we celebrate our 3rd Manufacturing Independence Day—marking the first GMP run at our REGENXBIO Manufacturing Innovation Center. The RMIC helps us move faster, think bigger, and stay focused on what matters most: bringing new medicines to patients.

At REGENXBIO, our leaders are deeply committed to science and to patients. Last week, several of them hosted a career panel for our interns and Learning Undefeated's Emerging Leaders. Their advice? Be curious, stay open, and embrace the unknown—there’s no one-size-fits-all path.

Meet Megana, another one of our 16 talented summer interns. This summer, she’s been contributing to our Gene Therapy Research team, supporting our ocular programs and learning alongside lead scientists in the lab. Outside of work, Megana is an avid dancer!

REGENXBIO Chief Commercial Officer, Dr. Ram Palanki, joined Dr. Firas Rahhal at Ophthalmology Innovation Source Retina to lead a panel on the future of healthcare innovation and investment—exploring market shifts, policy changes & global trends shaping retina care and beyond. Thank you Ophthalmology Innovation Source!

REGENXBIO will host a conference call on August 7th to discuss second quarter 2025 financial results and operational highlights. Learn more: ir.regenxbio.com/news-releases/…

Today, we announced a pivotal program for sura-vec in diabetic retinopathy using suprachoroidal delivery. Learn more: ir.regenxbio.com/news-releases/… $RGNX

REGENXBIO reports second quarter 2025 financial results and operational highlights. Learn more: ir.regenxbio.com/news-releases/… $RGNX